Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

12 January 2021

Helsinn Demonstrates Commitment to raising Awareness on Cachexia by Supporting Cachexia Societies Conferences

10 December 2020

Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor

9 December 2020

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area

1 December 2020

Quando in Svizzera mancano i Farmaci

27 October 2020

Helsinn receives Swiss Biotech Success Stories Award 2020

6 October 2020

Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)

23 September 2020

Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020

18 September 2020

Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program

10 September 2020

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution — now available in the US

20 August 2020